Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis:case report

Autor: Rikke Boedker Holmstroem, Emilie Kristine Dahl, Morten Helms, Henrik Vedel Nielsen, Janne Bayer Andersen, Jacob Tveiten Bjerrum, Inge Marie Svane, Eva Ellebaek, Jakob Benedict Seidelin

Publikováno v: Holmstroem, R B, Dahl, E K, Helms, M, Nielsen, H V, Andersen, J B, Bjerrum, J T, Svane, I M, Ellebaek, E & Seidelin, J B 2022, ' Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis : case report ', BMJ Open Gastroenterology, vol. 9, no. 1, e000989 . https://doi.org/10.1136/bmjgast-2022-000989

BackgroundImmune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.Case

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c058cd1452d0daf71f568c62b551a9
https://curis.ku.dk/portal/da/publications/tofacitinib-and-faecal-microbiota-transplantation-in-treating-checkpoint-inhibitorinduced-enterocolitis(9a254421-b5ef-4cb4-83ad-938ac9ad0619).html

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Autor: Monique C. Minnema, Margaret A. Shipp, Stephen M. Ansell, Nishitha Reddy, Scott J. Rodig, Jonathon B. Cohen, Selda Samakoglu, Kazunobu Kato, Margaretha G.M. Roemer, Sarit Assouline, Philippe Armand, Anne Sumbul, Michelle Poon, Peter Johnson, Azra H. Ligon, Manish Sharma, John M. Timmerman, Andrew Grigg

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(6), 481. American Society of Clinical Oncology

Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bd249e2e8165cc0d45938a170ea405
https://doi.org/10.1200/jco.18.00766

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Autor: Marija Gamulin, Eric Nham, Deni Rkman, Zrna Antunac, null Golubić, Robert Likić

Publikováno v: Croatian Medical Journal
Volume 61
Issue 4

Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d807a701ee3b39fe7fd1be726737505
https://www.bib.irb.hr/1263395

Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient

Autor: Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters

Publikováno v: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)

Background Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90
https://pubmed.ncbi.nlm.nih.gov/31791418

A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors

Autor: Corina Andreescu, Brigitte Velkeniers, Filip Cools, Bert Bravenboer, Filette Jeroen de

Publikováno v: Vrije Universiteit Brussel

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies. The incidence of endocrine adverse events provoked by these immune che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41dcb189faa29cc75e42e1c8e1320de4
https://biblio.vub.ac.be/vubir/a-systematic-review-and-metaanalysis-of-endocrinerelated-adverse-events-associated-with-immune-checkpoint-inhibitors(8b681d29-842a-49a9-b1b4-d31fdd4a04aa).html